RxDoctor Payments Data

Diana Dang, MD

Obstetrics & Gynecology · New Orleans, LANPI 1073870986

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (36.1%), education and speaking fees — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Intuitive Surgical at 48.2% of the total. Reporting peaked in 2022 at $8,259 and has fallen 87.5% since, to $1,035 in 2025. Among obstetrics & gynecology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,747in general payments, 2019–2025

Across 347 payments — averaging $48.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$8K
  • Organon$3K
  • AbbVie$863
  • Mayne Pharma Commercial LLC$736
  • Astellas Pharma US Inc$591
  • Exeltis, USA Inc.$433
  • plus $3K from 36 others

What the payments were for

  • Speaking & faculty fees$2,75016%
  • Travel & lodging$2,17213%
  • Food & beverage$6,05336%
  • Education$5,77234%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,747 in reported general payments places this provider in the 95th percentile of 608 obstetrics & gynecology providers in Louisiana.

See all obstetrics & gynecology providers in Louisiana

Medicare billing

Part B allowed, 2024
$3,782
Medicare patients
38
Services billed
66

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron31$17,308
Estradiol79$4,884
CombipatchEstradiol/Norethindrone Acet12$2,833
Estradiol (Twice Weekly)Estradiol18$1,187
Ibandronate Sodium16$423
Oxybutynin Chloride ErOxybutynin Chloride27$336
Alendronate Sodium61$311
ValacyclovirValacyclovir Hcl11$207
Venlafaxine Hcl ErVenlafaxine Hcl22$155
Escitalopram Oxalate13$100
Triamcinolone Acetonide12$82

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$591$17,30831 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 608 obstetrics & gynecology providers in Louisiana.

Other obstetrics & gynecology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →